Investing.comCodex · 实盘不做把握 2/10
北京时间·🕒 发布 18:56:33时区推断·⟳ 抓取 18:59:09·⚡ 决策 07-22 19:02:38 +3m29s·97.2 天前
Pharvaris发布缓激肽B2受体研究综述文章
本次只是公司发布/转发一篇综述文章，未披露临床读出、监管进展、商业化数据或融资交易。
📄 原文Investing.com↗ 原文
Pharvaris publishes review on bradykinin B2 receptor research
Oil price tops $95 for first time since June 11 amid widening Mideast conflict ZUG, Switzerland - Pharvaris (NASDAQ:PHV…
不做 Pharvaris（PHVS.US）
综述文章发布属于品牌/科研传播，无临床数据、审批、订单或商业化增量，无法形成正期望交易，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 low · price-in 风险 medium ↗
关键理由
- 本次只是公司发布/转发一篇综述文章，未披露临床读出、监管进展、商业化数据或融资交易。
- 事件内容偏科学与品牌传播，不能形成对Pharvaris（PHVS.US）短期收入、利润或估值的新增可量化催化。
主要风险
- 若后续出现同一管线的临床三期数据、FDA沟通或合作授权，需按新事件重新研判。
原文全文
展开原文 · 2,088 字
Oil price tops $95 for first time since June 11 amid widening Mideast conflict
ZUG, Switzerland - Pharvaris (NASDAQ:PHVS) announced today the publication of a review article in Clinical Reviews in Allergy & Immunology examining the biology of bradykinin and the bradykinin B2 receptor, according to a press release statement.
The article provides an overview of scientific and clinical research on bradykinin B2 receptor antagonism as a therapeutic approach for bradykinin-mediated diseases. The review traces the development of this therapeutic strategy from early discoveries in kinin biology to clinical applications.
"The long history of scientific and clinical evidence demonstrates that bradykinin B2 receptor antagonism is a validated and foundational therapeutic approach in the management of bradykinin-mediated angioedema," said Anne Lesage, Chief Early Development Officer of Pharvaris.
The article discusses the role of bradykinin and the bradykinin B2 receptor in conditions including bronchial asthma, chronic cough, allergic rhinitis, and chronic urticaria. According to the company, there have been no observations of increased risks of long-term unfavorable effects from the antagonism of the bradykinin B2 receptor to date.
The review examines how bradykinin B2 receptor antagonists work by blocking the receptor through which bradykinin exerts its effects, targeting the mediator of swelling regardless of the upstream mechanism driving excess bradykinin production.
The article covers the established role of this approach in hereditary angioedema, including HAE with normal C1 inhibitor, and acquired angioedema due to C1 inhibitor deficiency.
Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated conditions. The company’s product candidates include deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ZUG, Switzerland - Pharvaris (NASDAQ:PHVS) announced today the publication of a review article in Clinical Reviews in Allergy & Immunology examining the biology of bradykinin and the bradykinin B2 receptor, according to a press release statement.
The article provides an overview of scientific and clinical research on bradykinin B2 receptor antagonism as a therapeutic approach for bradykinin-mediated diseases. The review traces the development of this therapeutic strategy from early discoveries in kinin biology to clinical applications.
"The long history of scientific and clinical evidence demonstrates that bradykinin B2 receptor antagonism is a validated and foundational therapeutic approach in the management of bradykinin-mediated angioedema," said Anne Lesage, Chief Early Development Officer of Pharvaris.
The article discusses the role of bradykinin and the bradykinin B2 receptor in conditions including bronchial asthma, chronic cough, allergic rhinitis, and chronic urticaria. According to the company, there have been no observations of increased risks of long-term unfavorable effects from the antagonism of the bradykinin B2 receptor to date.
The review examines how bradykinin B2 receptor antagonists work by blocking the receptor through which bradykinin exerts its effects, targeting the mediator of swelling regardless of the upstream mechanism driving excess bradykinin production.
The article covers the established role of this approach in hereditary angioedema, including HAE with normal C1 inhibitor, and acquired angioedema due to C1 inhibitor deficiency.
Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated conditions. The company’s product candidates include deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。